Abstract:Breast cancer resistance to the antiestrogens tamoxifen (OHT) and fulvestrant is accompanied by alterations in both estrogen-dependent and estrogen-independent signaling pathways. Consequently, effective inhibition of both pathways may be necessary to block proliferation of antiestrogen -resistant breast cancer cells. In this study, we examined the effects of apigenin, a dietary plant flavonoid with potential anticancer properties, on estrogen-responsive, antiestrogen-sensitive MCF7 breast cancer cells and two MCF7 sublines with acquired resistance to either OHT or fulvestrant. We found that apigenin can function as both an estrogen and an antiestrogen in a dose-dependent manner. At low concentrations (1 mu mol/L), apigenin stimulated MCF7 cell growth but had no effect on the antiestrogen-resistant MCF7 sublines. In contrast, at high concentrations (> 10 mu mol/L), the drug inhibited growth of MCF7 cells and the antiestrogen-resistant sublines, and the combination of apigenin with either OHT or fulvestrant showed synergistic, growth-inhibitory effects on both antiestrogen-sensitive and anti estrogen -resistant breast cancer cells. To further elucidate the molecular mechanism of apigenin as either an estrogen or an antiestrogen, effects of the drug on estrogen receptor-alpha (ER alpha); transactivation activity, mobility, stability, and ER alpha-coactivator interactions were investigated. Low-dose apigenin enhanced receptor transcriptional activity by promoting interaction between ER alpha and its coactivator amplified in breast cancer-1. However, higher doses (> 10 mu mol/L) of apigenin inhibited ER alpha mobility (as determined by fluorescence recovery after photobleaching assays), down-regulated ER alpha and amplified in breast cancer-1 expression levels, and inhibited multiple protein kinases, including p38, protein kinase A, mitogen-activated protein kinase, and AKT. Collectively, these results show that apigenin can function as both an antiestrogen and a protein kinase inhibitor with activity against breast cancer cells with acquired resistance to OHT or fulvestrant. We conclude that apigenin, through its ability to target both ER alpha-dependent and ER alpha-independent pathways, holds promise as a new therapeutic agent against antiestrogen-resistant breast cancer.

Apigenin in Cancer Therapy: Anti-Cancer Effects and Mechanisms of Action

Anticancer Mechanism of Apigenin and the Implications of GLUT-1 Expression in Head and Neck Cancers

Apigenin's anticancer properties and molecular mechanisms of action: Recent advances and future prospectives

Anti-proliferation and Chemo-Sensitization Effects of Apigenin on Human Lung Cancer Cells

The Anticancer Potential of Apigenin Via Immunoregulation

Apigenin Inhibits the Proliferation of Adenoid Cystic Carcinoma Via Suppression of Glucose Transporter-1

Apigenin Suppresses Glut-1 And P-Akt Expression To Enhance The Chemosensitivity To Cisplatin Of Laryngeal Carcinoma Hep-2 Cells: An In Vitro Study

Apigenin and its nanoformulations for ameliorating normal tissue toxicity and enhancing tumor response to therapy: A mechanistic viewpoint

Progress in Anti-Tumor Mechanisms of Apigenin

Apigenin inhibits migration and invasion via modulation of epithelial mesenchymal transition in prostate cancer.

Apigenin role as cell-signaling pathways modulator: implications in cancer prevention and treatment

A comprehensive view on the apigenin impact on colorectal cancer: Focusing on cellular and molecular mechanisms

Apigenin promotes apoptosis, inhibits invasion and induces cell cycle arrest of T24 human bladder cancer cells

Autophagy Inhibition Enhances Apigenin-Induced Apoptosis in Human Breast Cancer Cells.

Research Progress in Mechanism of Apigenin' S Anticarcinogenic Activity on Cancer Cells

Experimental evidence for anti-metastatic actions of apigenin: a mini review

Apigenin Inhibits Expression of Vascular Endothelial Growth Factor and Angiogenesis in Human Lung Cancer Cells: Implication of Chemoprevention of Lung Cancer

Pharmacological Properties of 4′, 5, 7-Trihydroxyflavone (Apigenin) and Its Impact on Cell Signaling Pathways

Apigenin promotes apoptosis of 4T1 cells through PI3K/AKT/Nrf2 pathway and improves tumor immune microenvironment in vivo

Apigenin Inhibits Antiestrogen-Resistant Breast Cancer Cell Growth Through Estrogen Receptor-Α-dependent and Estrogen Receptor-Α-independent Mechanisms

Apigenin's Modulation of Doxorubicin Efficacy in Breast Cancer